Vir Biotechnology Files 8-K

TL;DR

Vir Bio filed a routine 8-K, no major news.

AI Summary

Vir Biotechnology, Inc. filed an 8-K on June 26, 2024, to report other events and financial statements/exhibits. The filing does not detail specific transactions or events beyond its routine reporting nature.

Why It Matters

This 8-K filing indicates routine corporate reporting by Vir Biotechnology, Inc. to the SEC, without disclosing specific material events.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting events and exhibits, not indicating any specific negative or positive material changes.

Key Players & Entities

• Vir Biotechnology, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• 001-39083 (company_id) — Commission File Number
• 81-2730369 (company_id) — IRS Employer Identification No.
• 1800 Owens Street, Suite 900 (address) — Principal executive offices
• San Francisco, California 94158 (address) — Principal executive offices
• 415-906-4324 (phone_number) — Registrant's telephone number
• June 26, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value VIR Nasdaq Global Select

Filing Documents

• d835539d8k.htm (8-K) — 28KB
• d835539dex991.htm (EX-99.1) — 14KB
• g835539g0626060813808.jpg (GRAPHIC) — 2KB
• 0001193125-24-168554.txt ( ) — 172KB
• vir-20240626.xsd (EX-101.SCH) — 3KB
• vir-20240626_lab.xml (EX-101.LAB) — 18KB
• vir-20240626_pre.xml (EX-101.PRE) — 11KB
• d835539d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements This disclosure, including the press release filed herewith as Exhibit 99.1, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "plan," "potential," "aim," "expect," "anticipate," "promising" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir's expectations and assumptions as of the date of this Current Report on Form 8-K. Forward-looking statements contained herein include, but are not limited to, statements regarding the Company's strategy and plans, the potential clinical effects, benefits, safety and efficacy of tobevibart and elebsiran, the timing, nature and significance of data from the Company's multiple ongoing trials evaluating tobevibart and elebsiran, including the previously announced Phase 2 SOLSTICE data, the timing of any further releases of data or of any presentations or investor conference calls, the Company's plans and expectations for its chronic hepatitis delta and chronic hepatitis B programs, the Company's ability to realize the benefits from receiving the Fast Track Designation from the FDA, and risks and uncertainties associated with drug development and commercialization. Many factors may cause differences between current expectations and actual results, including that the Fast Track Designation might not result in a more expedited development or regulatory review process, and such a designation does not increase the likelihood that the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta infection will receive marketing approval in the United States; the Fast Track Designation does not change the standards for regulatory approval; the FDA may later decide that the combination of tobevibart and elebsiran for the treatment o

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company, dated June 26, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIR BIOTECHNOLOGY, INC. Date: June 26, 2024 By: /s/ Marianne De Backer Marianne De Backer, M.Sc., Ph.D., MBA Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR